Trial · NCT02006849
ACTH Treatment of APOL1- Associated Nephropathy
NCT02006849, Not applicable, Withdrawn, Wake Forest University Health Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ACTH Treatment of APOL1- Associated Nephropathy. Trials, record NCT02006849. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02006849
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ACTH Treatment of APOL1- Associated Nephropathy
- NCT number
- NCT02006849
- Status
- Withdrawn
- Phases
- Not applicable
- Enrollment
- 0 participants, actual
- Lead sponsor
- Wake Forest University Health Sciences
- Conditions
- Kidney Disease
- Interventions
- Acthar
- First posted
- 2013-12-10
- Last updated
- 2017-11-07
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in proteinuria with H.C. Acthar gel | End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment) | Complete remission (CR) (UPCR \<0.2g/g) or partial remission (PR) (50% drop in UPCR from baseline) of proteinuria at the end of Treatment period in patients with baseline nephrotic proteinuria |
| Primary | Change in proteinuria with H.C. Acthar gel | End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment) | Percent change in proteinuria at the end of Treatment period in patients with baseline sub-nephrotic proteinuria |
| Primary | Change in eGFR with H.C. Acthar gel | End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment) | Percent change in Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR at the end of Treatment period |
| Secondary | Percent change in proteinuria | 1 year and 2 years of study follow-up after treatment completion | Percent change in proteinuria after 1 year and 2 years of follow-up |
| Secondary | Percent change in CKD-EPI eGFR | 1 year and 2 years of study follow-up after treatment completion | Percent change in CKD-EPI eGFR at 1 and 2 years of study follow-up |
| Secondary | Change in CKD-EPI eGFR | 1 year and 2 years of study follow-up after treatment completion | Change in eGFR over time, based on baseline proteinuria (nephrotic vs. sub-nephrotic), baseline eGFR (eGFR 30-45 vs. eGFR 45-59), and Acthar dose |
| Secondary | Duration of remission after H.C. Acthar gel treatment | 1 year and 2 years of study follow-up after treatment completion | Proportion of patients with baseline nephrotic proteinuria who sustained CR or PR at 1 and 2 years of study follow-up |
| Secondary | Changes in kidney fibrosis after H.C. Acthar gel treatment | End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment) | Modifications in kidney histopathology on second post-treatment kidney biopsy (% glomerulosclerosis, % tubulointerstitial fibrosis, restoration of podocyte markers \[e.g.,podocin, synaptopodin, Wilms tumor 1\]) compared with baseline biopsy |
| Secondary | Cholesterol and lipoprotein profile before and after treatment with H.C. Acthar gel | End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment) | Changes in cholesterol and lipoprotein levels compared with baseline profiles |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02006849
GET https://conductscience.org/api/trials/v1/NCT02006849/registered